secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001437749-24-005904
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra Therapeutics amends bylaws to address universal proxy rules and update stockholder meeting procedures
--------------------------------------------------------------------------------

- Board approved amended and restated bylaws effective February 22, 2024.
- Amendments incorporate SEC universal proxy rules (Rule 14a-19) for director nominations.
- Requires stockholders soliciting proxies to use a non-white proxy card.
- Includes technical and conforming changes to reflect updates in Delaware General Corporation Law.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924005904/0001437749-24-005904-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924005904/zvra20240228_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-005904

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer